Registered title, quoted from ClinicalTrials.gov
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Pulmonary Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07874581, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically confirmed small cell lung cancer (SCLC);
Inclusion criterion 3
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Inclusion criterion 6
History of drug abuse, chronic alcohol abuse, AIDS, or HIV infection;
Exclusion criterion 4
History of malignancy within the previous 3 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ with an expected survival of >3 years, such as breast cancer in situ, oral carcinoma in situ, or cervical carcinoma in situ;
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07874581, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Signed informed consent form (ICF);
- Age ≥18 years at the time of signing informed consent;
- Histologically confirmed small cell lung cancer (SCLC);
- Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment;
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Adequate organ and bone marrow function.
- Women of childbearing potential must use highly effective contraception from screening until 3 months after discontinuation of study treatment and must have a negative pregnancy test (serum or urine) within 7 days before enrollment. Male participants must agree to use appropriate contraception from screening until 3 months after discontinuation of study treatment or have undergone surgical sterilization;
- No anticancer therapy was received within the specified washout period before the first dose of study treatment;
- Estimated life expectancy ≥12 weeks.
Exclusion Criteria:
- Known hypersensitivity to becotatug vedotin;
- History of another active malignancy requiring treatment or history of allogeneic organ transplantation;
- Major surgery (excluding diagnostic biopsy) within 4 weeks before the first dose of study treatment;
- History of drug abuse, chronic alcohol abuse, AIDS, or HIV infection;
- Active autoimmune disease or history of autoimmune disease with potential risk of recurrence;
- Current systemic corticosteroid therapy (e.g., prednisone equivalent >10 mg/day) or use of any other immunosuppressive therapy within 14 days before the first dose of study treatment;
- Interstitial lung disease (ILD), or previous ILD requiring corticosteroid treatment;
- History of idiopathic pulmonary fibrosis (IPF), drug-induced pneumonitis, organizing pneumonia (including bronchiolitis obliterans organizing pneumonia), or idiopathic pneumonia;
- Receipt of live vaccines within 28 days before the first dose of study treatment;
- Any disease or condition that may contraindicate anticancer therapy, including but not limited to active infection, myocardial infarction within 6 months, symptomatic cardiac disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmia), or ongoing immunosuppressive therapy;
- Pregnancy or breastfeeding; or male or female participants unwilling to use appropriate contraception when pregnancy is possible;
- Evidence of hereditary bleeding disorders or coagulation abnormalities;
- History of malignancy within the previous 3 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ with an expected survival of >3 years, such as breast cancer in situ, oral carcinoma in situ, or cervical carcinoma in situ;
- Any other medical history, disease, treatment, or laboratory abnormality that may interfere with study results, prevent full participation in the study, or make the participant unsuitable for enrollment as judged by the investigator.
Quoted from ClinicalTrials.gov, NCT07874581, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07874581, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.